(Q38031989)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Sara Bringhen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Chiara Pautasso

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Chiara Cerrato

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mario Boccadoro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

3 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1209-1222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

How I treat multiple myeloma in younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

IMiDs: a novel class of immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

21 January 2018

Immunomodulatory drugs.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide in the treatment of multiple myeloma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Risky business in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Management of older patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide in multiple myeloma: current role and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.712685

10.1517/17425255.2012.712685

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22862790%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference